GLP-1 pills are coming, and they could revolutionize weight-loss
Sep 17, 2024 · The new crop of GLP-1 weight loss drugs all come in the form of injections. New pill versions are in trials now.
Beyond Ozempic: New GLP-1 drugs promise weight loss and …
Drug companies are racing to develop GLP-1 drugs following the blockbuster success of Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound. Some of the experimental drugs...
Greater Access to GLP-1 Meds Could Save Thousands of Lives Per …
Oct 24, 2024 · Glucagon-like peptide-1 (GLP-1) drugs mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food. However, the drugs are costly -- people without insurance face paying more than …
Many people using GLP-1s for weight loss stop treatment too soon ... - CNN
May 21, 2024 · An analysis of health insurance claims released Tuesday found that most people using GLP-1 medications – about 58% – were on their treatment plan for less than 12 weeks, falling short of a key...
Weight-loss drugs like Wegovy may help stave off some cancers - NPR
Aug 12, 2024 · Several new studies find promising evidence that the GLP-1 class of drugs may have a cancer-preventive effect, especially for cancers linked to obesity.
Victoza: Generic GLP-1 Drug Similar to Ozempic Now Available - Healthline
Jul 3, 2024 · A new generic of the GLP-1 drug Victoza, which is similar to popular medications like Ozempic, Wegovy, Mounjaro, and Zepbound, is now available in the United States.
FDA clarifies policies for compounders as national GLP-1 supply …
The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.
How Ozempic, other weight-loss drugs are "changing medicine"
Jan 21, 2024 · GLP-1 class medications reduce cardiovascular risk and treat diabetes. But they also allow people to lose an average of 10-20 percent of their body weight in the first year.
The Crackdown on Compounded GLP-1 Meds Has Begun
Oct 10, 2024 · Eli Lilly has sent cease-and-desist letters to hundreds of compounding pharmacies, telehealth companies, and medical spas making and selling “compounded” versions of tirzepatide.
HRS9531 is a dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, offering a treatment option for individuals with overweight or obesity, as well as type 2 diabetes. This Phase 2 study evaluated the efficacy and safety of …